Australia's most trusted
source of pharma news
Sunday, 19 May 2024
Posted 22 February 2023 PM
Pfizer and BioNTech have joined forces again, aiming to muscle in on another lucrative market announcing a trial of the first mRNA-based vaccine for the prevention of Shingles is under way.
A Phase 1/2 study kicked off this month exploring the safety, tolerability, and immunogenicity of their mRNA candidates against the debilitating condition which affects millions of people globally each year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.